Jurgen Drews - Net Worth and Insider Trading

Jurgen Drews Net Worth

The estimated net worth of Jurgen Drews is at least $0 dollars as of 2024-04-26. Jurgen Drews is the Director of PDL BioPharma Inc and owns about 0 shares of PDL BioPharma Inc (PDLI) stock worth over $0. Details can be seen in Jurgen Drews's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jurgen Drews has not made any transactions after 2004-05-28 and currently still holds the listed stock(s).

Transaction Summary of Jurgen Drews

Jurgen Drews Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jurgen Drews owns 1 companies in total, including PDL BioPharma Inc (PDLI) .

Click here to see the complete history of Jurgen Drews’s form 4 insider trades.

Insider Ownership Summary of Jurgen Drews

Ticker	Comapny	Transaction Date	Type of Owner
PDLI	PDL BioPharma Inc	2004-05-28	director

Jurgen Drews Latest Holdings Summary

Jurgen Drews currently owns a total of 1 stock. Jurgen Drews owns 0 shares of PDL BioPharma Inc (PDLI) as of May 28, 2004, with a value of $0.

Latest Holdings of Jurgen Drews

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PDLI	PDL BioPharma Inc	2004-05-28	0	2.47	0

Holding Weightings of Jurgen Drews

Jurgen Drews Form 4 Trading Tracker

According to the SEC Form 4 filings, Jurgen Drews has made a total of 0 transactions in PDL BioPharma Inc (PDLI) over the past 5 years. The most-recent trade in PDL BioPharma Inc is the sale of 70,000 shares on May 28, 2004, which brought Jurgen Drews around $1 Million.

Insider Trading History of Jurgen Drews

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jurgen Drews Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jurgen Drews Ownership Network

Ownership Network List of Jurgen Drews

No Data

Ownership Network Relation of Jurgen Drews

Jurgen Drews Owned Company Details

What does PDL BioPharma Inc do?

Who are the key executives at PDL BioPharma Inc?

Jurgen Drews is the director of PDL BioPharma Inc. Other key executives at PDL BioPharma Inc include President and CEO Dominique Monnet , VP & Gen. Counsel & Secretary Christopher Lewis Stone , and VP Finance & CAO and Acting CFO Edward Imbrogno .

PDL BioPharma Inc (PDLI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PDL BioPharma Inc (PDLI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PDL BioPharma Inc (PDLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PDL BioPharma Inc (PDLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

PDL BioPharma Inc Insider Transactions

No Available Data

Jurgen Drews Mailing Address

Above is the net worth, insider trading, and ownership report for Jurgen Drews. Currently GuruFocus does not have mailing address information for Jurgen Drews.

Discussions on Jurgen Drews

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.